2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Elutia completed the sale of its SimpliDerm breast reconstruction business, which made up substantially all of its Women's Health segment, to Cellution Biologics on August 17, 2026. The company received $7.7 million in cash at closing, subject to post-closing adjustments, with up to $3 million more in contingent payments. The filing says the company's 2025 and first-half 2026 pro forma continuing operations exclude the business, which had accounted for most of its reported net sales.
Net cash received at closing: $7.7 million, subject to post-closing inventory adjustments
Contingent payments of up to $3 million over the next 18 months, tied to technology transfer and commercial milestones
Pro forma six-month 2026 net sales from continuing operations: $2.2 million, versus $5.5 million as reported
Company expects to record an estimated gain of $4.9 million, which is not reflected in the pro forma periods
James River Group Holdings disclosed that director Kirstin M. Gould resigned effective immediately, with notice given on August 20, 2026, and that the resignation did not stem from a disagreement with the company. The company also furnished a second quarter 2026 investor presentation, which shows net income to common shareholders rose to $4.4 million from $2.8 million a year earlier, but an underwriting loss of $0.3 million and a six-month loss to common shareholders of $6.5 million.
Kirstin M. Gould resigned as a director effective immediately, as of August 20, 2026; the filing states no disagreement with the company.
2Q26 net income to common shareholders was $4.4 million, versus $2.8 million in 2Q25.
2Q26 underwriting result was a loss of $0.3 million, compared with a profit of $2.1 million in 2Q25.
Six months ended June 30, 2026: loss to common shareholders of $6.5 million, versus income of $10.4 million a year earlier; group combined ratio was 100.2% versus 98.6%.
WhiteFiber completed a $310.0 million private offering of 5.00% convertible senior notes due 2032 on August 21, 2026, including the full $40.0 million option. The company used about $118.5 million of the roughly $298.5 million in net proceeds to exchange $198.15 million of its 4.500% notes due 2031 for cash and about 6.3 million ordinary shares. The new notes add debt and could dilute shareholders on conversion, which the company can settle in cash, shares, or both, and the filing says more project financing will be needed.
$310.0 million principal of 5.00% notes maturing September 1, 2032, with semiannual interest starting March 1, 2027
Initial conversion price of about $33.84 per share, a premium of about 25% over the August 18, 2026 last sale price
Exchanged $198.15 million of 4.500% notes due 2031 for about $118.5 million cash and about 6.3 million ordinary shares, leaving about $31.85 million outstanding
Net proceeds of about $298.5 million; the company says it will require additional project financing, such as construction loans
Insteel Industries will close its Upper Sandusky, Ohio welded wire facility and move manufacturing to its remaining welded wire plants, with operations expected to cease by the end of October 2026. The company expects restructuring charges of about $4.6 million, and says the move is not expected to affect its revenue.
Up to 65 positions to be eliminated at the Upper Sandusky facility
Operations expected to cease by the end of October 2026
Expected restructuring charge of approximately $4.6 million, including $1.0 million asset impairment
Cash charges expected to begin in the first quarter of fiscal 2027
The Buckle reported results for the fiscal quarter ended August 1, 2026. Net sales rose 4.6% to $319.8 million, but net income fell to $44.4 million, or $0.87 per diluted share, from $45.0 million, or $0.89 per diluted share, a year earlier. Revenue growth was positive while profit declined slightly, so shareholders see higher sales alongside slightly lower earnings.
Q2 net sales up 4.6% to $319.8 million from $305.7 million; comparable store net sales up 2.1%
Q2 net income $44.4 million ($0.87 diluted EPS) versus $45.0 million ($0.89 diluted EPS) a year earlier
26-week net income $91.3 million ($1.79 diluted EPS) versus $80.2 million ($1.59 diluted EPS) in the prior-year period
Store count was 446 at quarter end versus 440 a year earlier
Marine Petroleum Trust declared a quarterly cash distribution of $0.095378 per unit, payable September 28, 2026, to unitholders of record on August 31, 2026. The payment is lower than the $0.096470 per unit paid last quarter, which the trust attributed to lower oil and natural gas production volumes, but higher than the $0.068097 per unit paid in the same quarter of 2025.
Distribution of $0.095378 per unit, payable September 28, 2026, to holders of record on August 31, 2026
Down from $0.096470 per unit last quarter; up from $0.068097 per unit in the same quarter of 2025
Versus last quarter: production volume decreased and oil prices realized increased, while natural gas prices realized decreased
Versus the same quarter of 2025: production volume and oil prices realized increased, while natural gas prices realized decreased
On August 21, 2026, Werewolf Therapeutics agreed to merge with Ambros Therapeutics, a clinical-stage biotechnology company developing neridronate for CRPS-1, in an all-stock transaction. Pre-merger Werewolf stockholders, other than private placement investors, are expected to own about 6.8% of the combined company, so the merger would substantially dilute their holdings. The deal is expected to close by the first quarter of 2027, subject to stockholder approvals, Nasdaq listing approval, an effective Form S-4 and other conditions.
Pre-merger Ambros stockholders are expected to own about 71.7% of the combined company, and private placement investors about 21.5%.
Implied valuations are $500.0 million for Ambros and $47.5 million for Werewolf.
A concurrent private placement of $150 million in gross proceeds is expected to close with the merger.
Termination fees are $20.0 million payable by Ambros and $1.9 million payable by Werewolf in certain circumstances.
Odysight.ai agreed on August 20, 2026 to sell 3,437,500 shares of common stock at $3.20 each in an underwritten public offering led by Roth Capital Partners, with gross proceeds expected to be $11 million before fees and expenses. The same day, the company terminated its June 5, 2026 at-the-market sales agreement with Roth, which had a capacity of up to $20 million and made no sales. The new offering adds shares outstanding and dilutes existing holders, while the company says proceeds will fund research and development, sales and marketing, and working capital.
Firm offering of 3,437,500 shares at $3.20 per share; closing expected on or about August 21, 2026.
Underwriters have a 30-day option to buy up to 515,625 additional shares.
Underwriting discount is 6.5% of gross proceeds; company will reimburse up to $75,000 of Roth's expenses.
Company and its directors and executive officers agreed to a 45-day lock-up on sales of common stock, with exceptions.
Streamex Corp. reported second-quarter 2026 results, including $0.1 million of gold lease income, its first income under its tokenized gold platform, and $41.8 million in total liquidity with no debt as of June 30, 2026. Operating cash burn was $1.6 million per month in the quarter, including about $0.5 million of non-recurring items, and the company expects about $1.1 million per month in the third quarter excluding those items. The filing gives no prior-period comparisons, net loss or per-share figures, so the results cannot be measured against earlier periods from this document alone.
Gold lease income of $0.1 million in Q2 2026, the company's first income under its tokenized gold platform
Total liquidity of $41.8 million at June 30, 2026, including $18.5 million in cash and marketable securities; no outstanding debt
Operating cash burn of $1.6 million per month in Q2, including about $0.5 million of non-recurring items; expected about $1.1 million per month in Q3 2026 excluding those items
Working capital of $32.8 million and total equity of $147.1 million at quarter-end
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.